Removing total body irradiation (TBI) from conditioning did not degrade efficacy in pediatric and young adult patients with B ...

Race was identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

Elranatamab-bcmm (Elrexfio) demonstrated poorer progression-free survival (PFS) but greater response rates vs eclistamab-cqyv (Tecvayli) in patients with relapsed/refractory multiple myeloma according ...

Nearly one-third of families of children receiving treatment for acute lymphoblastic leukemia (ALL) developed what researchers described as “catastrophic” financial toxicity during therapy, according ...

From clinical trials, to psychosocial needs, to care transitioning, adolescent and young adult patients with cancer face ...

The FDA has approved lisocabtagene maraleucel (liso-cel; Breyanzi) for the treatment of adult patients with relapsed or ...

After a radical hysterectomy and pelvic lymphadenectomy for early-stage cervical cancer, patients often face decisions about ...

The FDA has approved pirtobrutinib (Jaypirca) treatment for adults with relapsed/refractory chronic lymphocytic leukemia or ...

A patient acuity model drove efficient and safe staffing through data from a natural language processing model informed by ...

With evolving standards for handling hazardous drugs, nurses must comply with safety and handling guidelines.

The FDA approved the combination of durvalumab (Imfinzi) plus FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and ...